Compare Main Street Capital Corporation (MAIN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Main Street Capital Corporation trades at $53.36 (market cap $5.03B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Main Street Capital Corporation is far larger — about 5.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Main Street Capital Corporation pays a 5.91% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MAIN | MRVI | |
|---|---|---|
Market Cap | $5.03B | $972.90M |
Volume | 386,945 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $64.60 | $9.00 |
52-Week Low | $49.63 | $2.83 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $7.48B | $1.08B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $53.50, down 0.3% on the day, with a bearish technical signal and key support at $53. The stock shows strong profitability with an 80.77% net margin and a P/E of 10.8, but revenue declined slightly in 2025 to $592M. Recent quarterly earnings have been mixed, beating in Q2 2026 but missing in Q1. The company maintains a consistent dividend, with recent payments of $0.27-$0.30 per share.
The outlook is cautious; while MAIN's high margins and dividend yield near 7.9% appeal to income investors, bearish technicals, softening revenue, and a high proportion of analyst 'Hold' ratings suggest limited near-term upside. Risks include earnings volatility and sensitivity to interest rates, but the stock trades below the consensus price target of $58, offering potential appreciation if fundamentals stabilize.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
